TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31791389

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy-oriented psychoeducation and self-managed exposure exercises delivered in four manual-based appointments with a general practitioner, along with case management by a trained health care assistant and eHealth support.
Number of subjects: 1844

Group type: COMPARATOR
Intervention: Usual care from general practitioners.
Number of subjects: 1844

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy, case management, eHealth support (combined intervention).
Number of subjects: 1844
Study: 28082437

Group type: EXPERIMENTAL
Intervention: 18F‐FDG PET/CT
Number of subjects: 200

Group type: COMPARATOR
Intervention: CT
Number of subjects: 200
Study: 25546595

Group type: EXPERIMENTAL
Intervention: SEL program with mindfulness
Number of subjects: 99

Group type: COMPARATOR
Intervention: Regular social responsibility program
Number of subjects: 99
Study: 23989819

Group type: EXPERIMENTAL
Intervention: Minimized closed circuit coronary artery bypass grafting (MCABG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Off-pump CABG (OPCAB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional CABG (CCABG)
Number of subjects: 30
Study: 21790890

Group type: EXPERIMENTAL
Intervention: Thermal balloon ablation (TBA)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Laparoscopic supracervical hysterectomy (LSH)
Number of subjects: 68
Study: 19245970

Group type: EXPERIMENTAL
Intervention: Ablation of complex fractionated atrial electrograms (CFAEs) in Group C (n = 50)
Number of subjects: 119

Group type: COMPARATOR
Intervention: No further ablation in Group B (n = 50)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Antral pulmonary vein isolation (APVI) in Group A (n = 19)
Number of subjects: 119
Study: 17086764

Group type: EXPERIMENTAL
Intervention: Tilting
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study: 15536018

Group type: EXPERIMENTAL
Intervention: Lisinopril therapy for 2 months
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 19
Study: 11136273

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG) ingestion for 5 days before indometacin administration
Number of subjects: 16

Group type: COMPARATOR
Intervention: Heat-killed LGG ingestion for 5 days before indometacin administration
Number of subjects: 16

Group type: COMPARATOR
Intervention: Indometacin administration
Number of subjects: 16
Study: 9390698

Group type: EXPERIMENTAL
Intervention: ACTH treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low nerve growth factor levels in symptomatic infantile spasms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal nerve growth factor levels in cryptogenic etiology
Number of subjects: 0

Group type: COMPARATOR
Intervention: High nerve growth factor levels in symptomatic postinfectious etiology
Number of subjects: 0
Study: 8201379

Group type: EXPERIMENTAL
Intervention: ESHAP regimen (VP‐16 40 mg/m2/d for 4 days, methylprednisolone 500 mg IV daily for 5 days, Ara‐C 2 g/m2 IV on day 5, with cisplatin 25 mg/m2 IV for 4 days)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: ESHAP regimen
Number of subjects: 122
Study: 3606083

Group type: EXPERIMENTAL
Intervention: 100 mg rimantadine tablet (single dose) followed by 100 mg twice a day for 10 days (regimen 1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 100 mg rimantadine tablet (single dose) followed by 100 mg once a day for 10 days (regimen 2)
Number of subjects: 24
Study: 31196052

Group type: EXPERIMENTAL
Intervention: Fun For Wellness (FFW)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 900
Study: 28332374

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg) with 0.2% ropivacaine (0.2 mL/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl (1 μg/kg) with 0.2% ropivacaine (0.2 mL/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 26039935

Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 μg
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 μg with sulfonylureas
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 μg without sulfonylureas
Number of subjects: 159
Study: 23484524

Group type: EXPERIMENTAL
Intervention: Diet education plus t'ai chi (TC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Diet education
Number of subjects: 26
Study: 21595527

Group type: EXPERIMENTAL
Intervention: Sound generators
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Open ear hearing aids
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 91
Study: 20141706

Group type: EXPERIMENTAL
Intervention: 30 mg/d of lisdexamfetamine dimesylate
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: 50 mg/d of lisdexamfetamine dimesylate
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: 70 mg/d of lisdexamfetamine dimesylate
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: All lisdexamfetamine dimesylate groups
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate
Number of subjects: 420
Study: 17107241

Group type: EXPERIMENTAL
Intervention: Haloperidol (5.4 mg/day)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Risperidone (4 mg/day)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Olanzapine (15.3 mg/day)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 172

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 172
Study: 15116860

Group type: EXPERIMENTAL
Intervention: Early invasive approach with glycoprotein IIb/IIIa receptor blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Practice guidelines
Number of subjects: 0
Study: 12562840

Group type: EXPERIMENTAL
Intervention: Simvastatin and Niacin (S‐N)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Simvastatin and Niacin plus Antioxidants (S‐N+A)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Antioxidants alone
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 9474610

Group type: EXPERIMENTAL
Intervention: Topical anesthetic application
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Phentolamine infusion
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Topical capsaicin
Number of subjects: 50
Study: 8701596

Group type: EXPERIMENTAL
Intervention: Purified influenza virus (N2) neuraminidase vaccine (NAV)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional trivalent influenza vaccine, Fluogen (Parke‐Davis)
Number of subjects: 88
Study: 2225407

Group type: EXPERIMENTAL
Intervention: Single IMA grafting (group 1)
Number of subjects: 1063

Group type: COMPARATOR
Intervention: Multiple IMA grafting (group 2)
Number of subjects: 1063
Study: 27373

Group type: EXPERIMENTAL
Intervention: Mianserin 3 X 10 mg daily or 3 X 20 mg daily
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 31879752

Group type: EXPERIMENTAL
Intervention: Intermittent fasting (IF)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Paleo diet
Number of subjects: 250
Study: 31258920

Group type: EXPERIMENTAL
Intervention: Intermittent treatment (three times a week) with clarithromycin, rifampicin, and ethambutol for 1 year
Number of subjects: 140

Group type: COMPARATOR
Intervention: Daily treatment with clarithromycin, rifampicin, and ethambutol for 1 year
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Intermittent treatment
Number of subjects: 140
Study: 28987246

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 854

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 854

Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 854

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 854
Study: 26926538

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.01 mg/kg once daily) as adjunctive therapy after shock wave lithotripsy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Paracetamol only
Number of subjects: 120
Study: 24419109

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Fluorouracil
Number of subjects: 985

Group type: COMPARATOR
Intervention: Not applicable (completion of therapy)
Number of subjects: 985
Study: 22664978

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.375% 10 mL
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.375% 20 mL
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.375% 40 mL
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% 20 mL
Number of subjects: 185

Group type: COMPARATOR
Intervention: Ropivacaine 0.75% 5 mL
Number of subjects: 185
Study: 19619331

Group type: COMPARATOR
Intervention: Nedocromil or placebo
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (budesonide)
Number of subjects: 654
Study: 17719358

Group type: EXPERIMENTAL
Intervention: Fear of the future
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Physical limitations
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Problems with family or friends due to cancer
Number of subjects: 72
Study: 15232663

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12442238

Group type: EXPERIMENTAL
Intervention: Intravenous opiate analgesia
Number of subjects: 205

Group type: COMPARATOR
Intervention: Baseline (before analgesia)
Number of subjects: 205
Study: 9660383

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (12.5 to 25 mg/d) with step-up to atenolol (25.0 to 50.0 mg/d) or reserpine (0.05 to 0.10 mg/d)
Number of subjects: 4736

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4736
Study: 8704425

Group type: COMPARATOR
Intervention: Qi stagnation type of CHD
Number of subjects: 46

Group type: COMPARATOR
Intervention: Blood stasis type of CHD
Number of subjects: 46
Study: 30025991

Group type: EXPERIMENTAL
Intervention: Clenbuterol
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 27039945

Group type: EXPERIMENTAL
Intervention: Combined therapy (rosuvastatin 10 mg/day, candesartan 16 mg/day, hydrochlorothiazide 12.5 mg/day)
Number of subjects: 12705

Group type: COMPARATOR
Intervention: Dual placebo
Number of subjects: 12705
Study: 23816321

Group type: EXPERIMENTAL
Intervention: MNP without Ca
Number of subjects: 100

Group type: COMPARATOR
Intervention: MNP with Ca
Number of subjects: 100
Study: 23303315

Group type: EXPERIMENTAL
Intervention: Folic acid-iron (30 mg)
Number of subjects: 18775

Group type: EXPERIMENTAL
Intervention: Folic acid, iron, and 13 additional vitamins and minerals
Number of subjects: 18775

Group type: COMPARATOR
Intervention: Daily folic acid (400 μg)
Number of subjects: 18775
Study: 19833619

Group type: EXPERIMENTAL
Intervention: Laser ablation
Number of subjects: 43

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 43
Study: 18958980

Group type: EXPERIMENTAL
Intervention: Responsibility for misfortune
Number of subjects: 0
Study: 16574482

Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 220

Group type: COMPARATOR
Intervention: Stretching (Control)
Number of subjects: 220
Study: 12534314

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled-release preparation of VPA
Number of subjects: 0
Study: 10921541

Group type: EXPERIMENTAL
Intervention: PGE1 (0.02 approximately 0.05 microg x kg(‐1) x min(‐1))
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 19
Study: 8729154

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Multiple daily injections (MDIs)
Number of subjects: 225
Study: 1314910

Group type: EXPERIMENTAL
Intervention: Breast irradiation
Number of subjects: 837

Group type: COMPARATOR
Intervention: No radiation therapy (Control)
Number of subjects: 837
Study: 3905713

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30461644

Group type: EXPERIMENTAL
Intervention: Single B-mode ultrasound guidance
Number of subjects: 300

Group type: COMPARATOR
Intervention: Color Doppler ultrasound guidance
Number of subjects: 300
Study: 26469812

Group type: EXPERIMENTAL
Intervention: Collagen matrix (CMX) + coronally advanced flap (CAF)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Connective tissue graft (CTG) + coronally advanced flap (CAF)
Number of subjects: 17
Study: 26084342

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 202
Study: 22948127

Group type: EXPERIMENTAL
Intervention: Idiopathic epilepsy
Number of subjects: 3066

Group type: EXPERIMENTAL
Intervention: Symptomatic epilepsy
Number of subjects: 3066

Group type: EXPERIMENTAL
Intervention: Generalized seizures
Number of subjects: 3066

Group type: EXPERIMENTAL
Intervention: Partial seizures
Number of subjects: 3066

Group type: EXPERIMENTAL
Intervention: Simple partial seizures
Number of subjects: 3066

Group type: EXPERIMENTAL
Intervention: Complex partial seizures
Number of subjects: 3066

Group type: EXPERIMENTAL
Intervention: Mixed seizures
Number of subjects: 3066

Group type: COMPARATOR
Intervention: Rural population
Number of subjects: 3066

Group type: COMPARATOR
Intervention: Illiterate group
Number of subjects: 3066

Group type: EXPERIMENTAL
Intervention: Children and teenagers
Number of subjects: 3066
Study: 20223500

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: TNF-alpha inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abatacept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other biologic agents
Number of subjects: 0
Study: 18476421

Group type: EXPERIMENTAL
Intervention: Huangqi Fuzheng Decoction (HQFZD)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Aciclovir (Control group A)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Aciclovir plus interferon (Control group B)
Number of subjects: 84
Study: 16756149

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids and long acting beta2-agonists
Number of subjects: 91

Group type: COMPARATOR
Intervention: Healthy children (Control group)
Number of subjects: 91
Study: 16295138

Group type: EXPERIMENTAL
Intervention: Active teaching method using the Kardorff-Schnelle-Parker skin model (10-min demonstration on day 0 and day 14)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group receiving verbal instructions of the same duration
Number of subjects: 30
Study: 10641586

Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8898504

Group type: EXPERIMENTAL
Intervention: Knowledge and attitudes (cognitive factors)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Cognitive factors
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Brief Pain Inventory
Number of subjects: 122
Study: 1797953

Group type: EXPERIMENTAL
Intervention: 3 g/day of Andrographis paniculata
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 6 g/day of Andrographis paniculata
Number of subjects: 152

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 152
Study: 6418561

Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fenoterol plus sodium cromoglycate
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 29522174

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg
Number of subjects: 1717

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1717
Study: 27459266

Group type: EXPERIMENTAL
Intervention: CYD‐TDV (live‐attenuated, tetravalent dengue vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24099735

Group type: EXPERIMENTAL
Intervention: D4D prosocial behavior incentive (monetary donation to WFP based on ALT decrease)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional dietary and exercise intervention alone
Number of subjects: 25
Study: 23767865

Group type: EXPERIMENTAL
Intervention: Salacia extracts (500 mg/day)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Salacia leaves extract
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 20838237

Group type: EXPERIMENTAL
Intervention: Psychiatric counseling (Group A)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Standard clinical monitoring (Group B)
Number of subjects: 211
Study: 17765214

Group type: EXPERIMENTAL
Intervention: Inhibitory secondary task during the 'Eyes' pictorial test of Theory of Mind
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal 'Stories' task with concurrent executive function tasks
Number of subjects: 0
Study: 16794882

Group type: EXPERIMENTAL
Intervention: Individual approach in the care of people with dementia; specific details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual everyday situations for residents; specific details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Communication between nurses and residents; specific details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Personal attention from nurses; specific details on dosage and duration not available.
Number of subjects: 0
Study: 15285076

Group type: EXPERIMENTAL
Intervention: Carotid Endarterectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid Angioplasty with primary stenting and cerebral protection
Number of subjects: 0
Study: 11189683

Group type: EXPERIMENTAL
Intervention: Digital rectal examination and blood test for prostate-specific antigen (PSA) for prostate cancer
Number of subjects: 148000

Group type: EXPERIMENTAL
Intervention: Posteroanterior view chest X‐ray for lung cancer
Number of subjects: 148000

Group type: EXPERIMENTAL
Intervention: 60‐cm flexible sigmoidoscopy for colorectal cancer
Number of subjects: 148000

Group type: EXPERIMENTAL
Intervention: Blood test for CA125 tumor marker and transvaginal ultrasound for ovarian cancer
Number of subjects: 148000

Group type: COMPARATOR
Intervention: Usual care for control group
Number of subjects: 148000
Study: 9314997

Group type: EXPERIMENTAL
Intervention: 50-125 mL of 60% nonionic contrast material pushed with 50 mL of saline
Number of subjects: 75

Group type: COMPARATOR
Intervention: 125 mL of 60% nonionic contrast material administered alone
Number of subjects: 75
Study: 8499429

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 3303916

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Less than college education
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Cholesterol
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Lower body mass index
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Age, lower education, lower body mass index, baseline electrocardiographic abnormalities
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Age, lower education, history of cardiovascular event, smoking
Number of subjects: 551

Group type: COMPARATOR
Intervention: Sex
Number of subjects: 551
Study: 28597693

Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy + mental practice
Number of subjects: 14

Group type: COMPARATOR
Intervention: Modified constraint-induced movement therapy
Number of subjects: 14
Study: 26514341

Group type: EXPERIMENTAL
Intervention: Decompression surgery between two and three months after onset (group I)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Follow-up observation (group III)
Number of subjects: 41
Study: 25218311

Group type: EXPERIMENTAL
Intervention: Generic clopidogrel bisulfate
Number of subjects: 90

Group type: COMPARATOR
Intervention: Branded clopidogrel bisulfate
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 90
Study: 22536843

Group type: EXPERIMENTAL
Intervention: STAN® (index group)
Number of subjects: 5681

Group type: COMPARATOR
Intervention: Cardiotocography (control group)
Number of subjects: 5681
Study: 20532167

Group type: EXPERIMENTAL
Intervention: Clinician-assisted iCBT
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Technician-assisted iCBT
Number of subjects: 150

Group type: COMPARATOR
Intervention: Delayed treatment (control group)
Number of subjects: 150
Study: 18612259

Group type: EXPERIMENTAL
Intervention: Intervention workshop for coaches
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control workshop for coaches
Number of subjects: 0
Study: 15836683

Group type: EXPERIMENTAL
Intervention: Vertical Infraclavicular Plexus Block (VIP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: High Axillary Plexus Block (HAP)
Number of subjects: 30
Study: 12415196

Group type: EXPERIMENTAL
Intervention: 5‐FU/LEV, weekly, 12 months
Number of subjects: 180

Group type: COMPARATOR
Intervention: 5‐FU/FA, days 1‐5, every 4 weeks, 12 months
Number of subjects: 180

Group type: COMPARATOR
Intervention: 5‐FU/FA, days 1‐5, every 4 weeks, 6 months
Number of subjects: 180
Study: 10503821

Group type: EXPERIMENTAL
Intervention: Omeprazole-metronidazole-clarithromycin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metronidazole-resistance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omeprazole addition
Number of subjects: 0
Study: 8565748

Group type: EXPERIMENTAL
Intervention: 15 million units of interferon-alpha 2b per week for 24 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 22.5-30 million units of interferon-alpha 2b per week for 24 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-dose interferon therapy
Number of subjects: 24
Study: 2008690

Group type: EXPERIMENTAL
Intervention: Hydrocolloid occlusive bandage (DuoDERM ConvaTec, Squibb)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 38
Study: 6761637

Group type: EXPERIMENTAL
Intervention: Indomethacin therapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47